PROTACs for Autoimmune Diseases

Autoimmune diseases arise from dysregulated immune responses in which the body's own defense mechanisms mistakenly attack healthy tissues. Key signaling proteins that drive these pathological processes, including IRAK4 in Toll-like receptor and interleukin-1 receptor pathways, BTK in B cell receptor signaling, and various JAK-STAT family members in cytokine signaling, represent compelling yet difficult-to-drug targets for traditional small-molecule inhibition. PROTAC (PROteolysis TArgeting Chimera) technology offers a fundamentally different approach by inducing targeted protein degradation rather than mere catalytic inhibition, enabling the removal of entire scaffolding and signaling functions of disease-driving proteins. BOC Sciences provides comprehensive PROTAC development services specifically tailored for autoimmune and inflammatory disease targets, spanning target feasibility assessment, rational degrader design, synthesis optimization, and multi-tiered biological validation to accelerate research from target concept to optimized candidate molecules.

PROTAC Development Services for Autoimmune Disease

Autoimmune Target Feasibility Assessment

Selecting the right target is critical for autoimmune PROTAC projects due to the complexity and redundancy of immune signaling networks. We conduct systematic evaluations of protein expression patterns in relevant immune cell types, pathway architecture analysis, available ligand resource surveys, and preliminary degradability assessments using bioinformatic tools and structural modeling. These evaluations help determine whether a target possesses the structural accessibility, expression profile, and biological rationale necessary for effective PROTAC-mediated degradation in autoimmune disease contexts.

• Target expression profiling in immune cell populations
• Protein structure modeling and ligandability assessment
• Pathway redundancy and functional consequence analysis
• Degradability prediction using structural and sequence-based tools

Immune Signaling Protein Degrader Design

Based on target characteristics and intended mechanism, we design PROTAC architectures by matching validated warheads against target proteins with appropriate E3 ubiquitin ligase recruiters. For autoimmune targets, special consideration is given to immune cell-specific expression profiles of E3 ligases, the potential for selective degradation in disease-relevant cell types versus healthy tissues, and the preservation of desirable physiological immune functions while eliminating pathological signaling. Our design process integrates molecular docking, in silico protein-protein interaction modeling, and ternary complex stability prediction to prioritize high-probability candidates.

• Warhead selection and affinity optimization
• E3 ligase matching for immune cell context
• Molecular dynamics simulation of ternary complexes
• Selectivity assessment against related family members

E3 Ligase Selection for Immune Cell Contexts

The choice of E3 ligase profoundly influences PROTAC efficacy, selectivity, and therapeutic window, particularly in autoimmune indications where cell-type-specific degradation is highly desirable. We evaluate E3 ligase expression patterns across different immune cell subsets, including B cells, T cells, monocytes, macrophages, and dendritic cells, to identify ligases that are abundant in disease-relevant populations. Our platform supports systematic evaluation of CRBN, VHL, IAP, and MDM2-based strategies, among others, to identify the optimal E3 ligase recruit for each autoimmune target and project objective.

• E3 ligand design and screening across ligase families
• Immune cell-type-specific expression profiling
• Comparative degradation efficiency across E3 platforms
• Selectivity evaluation in mixed immune cell populations

Linker Engineering and Ternary Complex Optimization

Linker composition critically determines the geometry, stability, and cooperativity of the PROTAC-induced ternary complex between target protein and E3 ligase. We systematically optimize linker length, flexibility, and chemical composition, including PEG, alkyl, and cleavable linker strategies, to enhance ternary complex formation and degradation potency. For autoimmune targets, linker optimization also considers the specific spatial arrangement required for effective engagement of both target and ligase within the crowded environment of immune cell signaling complexes.

• Linker length and flexibility optimization
• Conjugation site evaluation on warhead and ligand
• Ternary complex stability and cooperativity assessment
• Structure-activity relationship guided linker refinement

Custom PROTAC Synthesis and Analog Expansion

We provide chemistry support ranging from the synthesis of individual target molecules to the preparation of focused analog libraries for structure-activity relationship exploration. Our synthesis capabilities accommodate diverse warhead chemistries, E3 ligase ligands, and linker architectures, enabling rapid generation of PROTAC series with systematic structural variations. Through coordinated chemistry and analytical support, we help clients explore chemical space efficiently and identify candidate molecules with optimal degradation potency and physicochemical properties.

• Target molecule and analog library synthesis
• Focused library design around hit structures
• Purity and structural characterization support
• Scale-up from milligram to gram quantities

Degradation Assay Development and Validation

Robust assay systems are essential for accurate evaluation of PROTAC-mediated degradation in autoimmune disease contexts. We develop and validate custom degradation assays tailored to specific target proteins and immune cell models, incorporating quantitative readouts for degradation potency (DC₅₀), maximal degradation (D_max), and degradation kinetics. Our assay development process ensures that measurement conditions appropriately capture the event-driven catalytic nature of PROTAC mechanisms while controlling for confounding factors such as cell permeability, compound stability, and target protein resynthesis rates.

• Cell-based degradation assay development
• DC₅₀ and D_max quantification methods
• Kinetic profiling and residence time analysis
• Assay validation for primary immune cell models

Autoimmune Disease Targets Supported by Our PROTAC Platform

BOC Sciences provides targeted degradation services for key immune signaling proteins involved in autoimmune disease research. Our platform supports target feasibility assessment, rational PROTAC design, immune cell-based validation, and functional pathway analysis across the following target categories.

Innate Immune Signaling Targets: IRAK4, RIPK2, and NLRP3

BOC Sciences supports PROTAC development for innate immune targets such as IRAK4, RIPK2, and NLRP3. Our team assesses target degradability, ligand resources, and structural accessibility before designing suitable degrader architectures. Candidate molecules are then tested in monocyte and macrophage models under TLR/IL-1R or NOD pathway stimulation to connect target degradation with inflammatory pathway response.

• Degradability prediction and ligand resource assessment for innate immune targets
• IRAK4 PROTAC design, synthesis, and optimization
• Degradation activity testing in monocyte and macrophage cell platforms
• Cytokine release inhibition validation under pathway-specific stimulation

B Cell Signaling Targets: BTK, SYK, and BLNK

Our platform supports degrader development for B cell receptor signaling proteins, including BTK, SYK, and BLNK. Starting from known inhibitors or ligand scaffolds, our team optimizes warhead selectivity, E3 ligase choice, and linker structure. Validation can include degradation assays in B cell models, activation marker analysis, and functional testing related to B cell signaling output.

• Warhead optimization and selectivity enhancement for B cell targets
• BTK PROTAC development with B cell selectivity profiling
• Primary B cell degradation activity and functional testing
• B cell activation, proliferation, and antibody production inhibition evaluation

Cytokine Pathway Targets: JAK1, JAK2, TYK2, and STAT3

BOC Sciences develops PROTAC strategies for cytokine pathway targets such as JAK1, JAK2, TYK2, and STAT3. The workflow focuses on isoform selectivity, target engagement, and pathway-specific degradation effects. Candidate degraders are evaluated under cytokine stimulation models through phosphorylation assays, STAT signaling analysis, and inflammatory gene expression readouts.

• JAK isoform-selective PROTAC molecular design
• STAT transcription factor degradation strategy development
• Pathway phosphorylation and functional testing under cytokine stimulation
• JAK family selectivity assessment and off-target degradation profiling

NF-κB Pathway Targets: IKKβ, NEMO, and RelA/p65

BOC Sciences supports PROTAC development for multiple NF-κB pathway nodes, including IKKβ, NEMO, and RelA/p65. Each target requires a different design strategy because kinase, regulatory, and transcriptional components have distinct structures and functions. Our validation system measures target degradation, pathway selectivity, inflammatory gene expression, and cross-pathway effects.

• Multi-node degradability assessment and prioritization for NF-κB targets
• IKKβ, NEMO, and RelA/p65 PROTAC design and optimization
• NF-κB pathway-selective degradation detection platform
• Inflammatory gene transcription inhibition functional validation

Interferon Signaling Targets: IRF3, IRF5, IRF7, and TBK1

Our team provides targeted degradation services for type I interferon signaling molecules, including TBK1, IRF3, IRF5, and IRF7. The workflow includes expression analysis, degradability assessment, PROTAC design, and validation in interferon-responsive cell models. Functional testing can include phosphorylation detection, interferon-stimulated gene expression analysis, and pathway response profiling.

• Interferon pathway target degradability assessment
• TBK1 and IRF family PROTAC molecular design
• Type I interferon stimulation models and ISG expression testing
• Antiviral and autoimmune function separation evaluation

T Cell Activation Targets: ZAP70, LCK, and NFAT Pathway Proteins

BOC Sciences supports degrader development for T cell activation targets such as ZAP70, LCK, and NFAT pathway proteins. Our team optimizes PROTAC permeability, intracellular exposure, and target degradation in T cell models. Validation can include proximal T cell receptor signaling, cytokine secretion, proliferation response, and subset selectivity analysis.

• PROTAC permeability optimization for T cell targets
• TCR signaling pathway degradation activity testing
• CD4⁺, CD8⁺, and regulatory T cell subset selectivity evaluation
• T cell activation, proliferation, and cytokine secretion functional validation

Our Solutions for Autoimmune PROTAC Development Challenges

Autoimmune PROTAC development presents unique challenges stemming from the complexity of immune signaling networks, the diversity of immune cell types, and the need to achieve therapeutic efficacy without compromising host defense. We provide integrated solutions that address these challenges at each stage of the development process.

Solution for Target Selection and Degradability Uncertainty

We reduce target selection risk through multi-layered assessments that combine bioinformatic degradability prediction, protein structural analysis, pathway context evaluation, and literature-based functional evidence. For autoimmune targets, we specifically evaluate the relative contribution of the target protein to disease-relevant signaling versus homeostatic immune functions, helping identify targets where degradation is most likely to produce the desired therapeutic effect while minimizing undesirable consequences. Our feasibility assessments provide clear, data-supported recommendations to guide project prioritization and resource allocation.

Solution for E3 Ligase Compatibility in Immune Cells

Successful PROTAC action requires adequate expression of the recruited E3 ligase in the cell types where target degradation is desired. We address this challenge by profiling E3 ligase expression across disease-relevant immune cell populations using publicly available transcriptomic datasets and, when needed, custom expression analysis. Based on these profiles, we prioritize E3 ligase candidates that show strong expression in target cells and design parallel evaluation strategies comparing multiple ligase options to identify the most productive pairing for each autoimmune target and indication.

Solution for Weak Ternary Complex Formation

Suboptimal ternary complex geometry frequently limits PROTAC potency and can be particularly challenging for targets with shallow or flexible binding surfaces common in immune signaling proteins. We systematically address this through linker length and flexibility screening, conjugation site variation on both warhead and ligand moieties, and rigidification strategies that constrain productive conformations. Our iterative approach combines computational prediction with experimental validation to identify linker architectures that promote stable, cooperative ternary complex formation and efficient ubiquitin transfer.

Solution for Poor Cellular Exposure of PROTAC Molecules

Many immune cells, particularly primary lymphocytes and tissue-resident macrophages, present formidable barriers to small-molecule entry due to efflux transporter expression and membrane composition. We optimize cellular exposure through multiparameter physicochemical property modulation, including molecular weight management, lipophilicity adjustment, hydrogen bond donor/acceptor optimization, and strategic introduction of charged or polar groups. For particularly challenging targets, we explore PROTAC delivery formulation strategies to enhance exposure in relevant immune cell populations.

Solution for Separating Target Degradation from Immune Suppression

A central concern in autoimmune PROTAC development is achieving sufficient target removal to dampen pathological signaling without creating broad immunosuppression that increases infection susceptibility. We address this through selectivity profiling against related protein family members, evaluation of degradation thresholds required for functional effect versus complete protein elimination, and pathway analysis to identify targets whose degradation preferentially affects disease-relevant signaling arms. Our approach emphasizes partial pathway modulation and cell-type-selective degradation strategies that preserve essential immune surveillance functions.

Solution for Iterative Optimization of Autoimmune PROTACs

Optimizing autoimmune PROTACs requires balancing degradation potency, selectivity, cellular permeability, and immune functional outcomes across multiple assay systems. We streamline this iterative process through integrated project management that coordinates parallel synthesis, analytical characterization, and biological testing workflows. Our optimization cycles incorporate structure-activity relationship analysis, structure-degradation relationship mapping, and functional readouts in relevant immune cell models to guide prioritization decisions and accelerate convergence on development-ready candidates.

PROTAC Validation Assays for Autoimmune Disease Models

Comprehensive validation of autoimmune-targeting PROTACs requires multi-tiered assay systems that confirm target engagement, degradation mechanism, and functional consequences in disease-relevant cellular contexts. We develop and execute integrated validation strategies that span biochemical, cellular, and immunological readouts.

Degradation Activity Testing: DC₅₀, D_max, and Degradation Kinetics

We quantify PROTAC-mediated degradation using standardized protocols that measure the half-maximal degradation concentration (DC₅₀) and maximal degradation achievable (D_max) across dose-response series. Kinetic profiling captures the time course of protein elimination and recovery, providing insights into the catalytic efficiency and residence time of the PROTAC-target-ligase interaction. These measurements are performed in engineered cell lines stably expressing tagged target proteins as well as endogenous expression systems to ensure relevance across different cellular contexts.

• Dose-response degradation curves with DC₅₀ determination
• D_max quantification via quantitative Western blot or ELISA
• Time-course kinetic analysis of protein removal and resynthesis
• PROTAC activity assay platform with multiple readout options

Target Protein Detection: Western Blot, ELISA, and Quantitative Proteomics

Accurate detection of target protein levels before and after PROTAC treatment is essential for reliable degradation assessment. We employ Western blot analysis for targeted protein quantification, Meso Scale Discovery ELISA platforms for high-sensitivity cytokine and protein detection, and mass spectrometry-based proteomics for unbiased assessment of degradation selectivity across the proteome. Global proteomic profiling is particularly valuable for identifying off-target degradation events and confirming the selectivity profile of autoimmune PROTAC candidates.

• Target-specific Western blot with loading control normalization
• High-sensitivity MSD ELISA for low-abundance proteins
• Global proteomics for selectivity and off-target profiling
• Target protein half-life measurement via cycloheximide chase

Target Engagement Testing: Cellular Thermal Shift Assay and Competitive Binding Analysis

Beyond degradation, confirming direct target engagement is critical for establishing the mechanism of action. We apply cellular thermal shift assays to detect compound-induced stabilization of target proteins in living cells, providing evidence of intracellular target binding. For certain targets, we also perform competitive binding experiments using fluorescent tracer displacement or surface plasmon resonance to quantify binding affinity and validate the warhead-target interaction that underlies degradation activity.

• Cellular thermal shift assay for intracellular engagement
• Fluorescent tracer displacement competition assays
• Surface plasmon resonance for binding kinetics
• Correlation of target engagement with degradation potency

Mechanism Confirmation Testing: Ubiquitination and Proteasome-Dependency Assays

Confirming that target degradation occurs through the expected ubiquitin-proteasome pathway is fundamental to establishing PROTAC mechanism. We detect PROTAC-enhanced target ubiquitination using immunoprecipitation followed by ubiquitin immunoblotting, and confirm proteasome dependency by demonstrating rescue of target protein levels upon treatment with proteasome inhibitors. For E3 ligase specificity, we perform knockout or knockdown experiments to verify that degradation requires the intended ligase, providing mechanistic rigor for the development candidate.

• Immunoprecipitation-Western blot for target ubiquitination detection
• Proteasome inhibitor rescue experiments
• E3 ligase knockdown/knockout dependency validation
• E3 ligase activity assay for functional confirmation

Immune Function Testing: Cytokine Release and Pathway Phosphorylation Readouts

For autoimmune PROTACs, functional validation must extend beyond target degradation to demonstrate meaningful impact on immune signaling outputs. We measure stimulus-induced cytokine release using multiplex ELISA and Luminex platforms, quantify pathway phosphorylation states using phospho-specific antibodies, and assess transcriptional changes through qPCR analysis of inflammatory gene expression. These functional readouts directly connect target degradation to the biological consequences relevant to autoimmune disease pathology.

• Multiplex cytokine profiling upon TLR, cytokine, or antigen stimulation
• Phospho-protein detection for pathway activation status
• Inflammatory gene expression analysis by qPCR
• Functional recovery upon target protein re-expression

Cell Model Validation: B Cell, Monocyte, Macrophage, and T Cell Assays

Immortalized cell lines provide useful early-stage data but may not recapitulate the biology of primary human immune cells. We validate autoimmune PROTAC activity across a hierarchy of cell models including engineered reporter cell lines, human peripheral blood mononuclear cell preparations, magnetically sorted primary B cells, monocytes, macrophages, and T cell subsets. This progressive validation strategy ensures that degradation activity and functional effects translate from simplified systems to physiologically relevant immune cell populations.

• PBMC-based degradation and functional assays
• Purified primary B cell, monocyte, and T cell assays
• Macrophage differentiation state-dependent degradation
• Mixed lymphocyte reaction and antigen-specific activation models

Workflow for Autoimmune PROTAC Development Projects

Autoimmune Disease Applications Supported by Our PROTACs

Case Studies: PROTAC Development for Autoimmune Targets

Why Choose BOC Sciences for Autoimmune PROTAC Projects?

End-to-End Development Support

We provide integrated PROTAC development services spanning target feasibility assessment, rational design, synthesis, and multi-tiered biological validation specifically tailored for autoimmune disease targets. Our platform eliminates the need to coordinate multiple vendors and ensures seamless project progression from concept to optimized candidates.

Flexible, Customized Solutions

Every autoimmune PROTAC project has unique requirements based on target biology, intended indication, and available resources. We tailor our service packages to accommodate diverse project scopes, from single-target feasibility studies to multi-target screening campaigns and comprehensive optimization programs.

Multi-Parameter Optimization Expertise

Autoimmune PROTACs require simultaneous optimization of degradation potency, selectivity against related immune signaling proteins, cellular permeability in primary immune cells, and functional impact on disease-relevant pathways. Our team applies systematic multiparameter optimization strategies to navigate these complex trade-offs efficiently.

Efficient Project Execution

We support faster project advancement through clear communication protocols, timely data reporting, and well-coordinated technical execution across our chemistry, analytical, and biology teams. Our project management ensures that synthesis, characterization, and testing workflows proceed in parallel with minimal downtime.

Strong PROTAC Platform and Experience

Our extensive experience in PROTAC design and development spans multiple target classes including kinases, transcription factors, and scaffolding proteins relevant to autoimmune pathology. We leverage established platforms for molecular design, synthesis, and biological evaluation to deliver reliable, reproducible results.

High-Quality Data and Decision Support

We provide robust, well-documented experimental data with clear analysis and interpretation to support informed decision-making at every stage. Our comprehensive reporting includes mechanistic insights, structure-activity relationships, and actionable recommendations for next-step optimization.